| scholarly article | Q13442814 |
| P50 | author | Mikhail Blagosklonny | Q17517010 |
| P2860 | cites work | Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation | Q41035793 |
| Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. | Q41205685 | ||
| Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats | Q41420657 | ||
| mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging | Q41809553 | ||
| STAT3, HIF-1, glucose addiction and Warburg effect | Q41819321 | ||
| The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway | Q41841005 | ||
| Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer | Q41970207 | ||
| Adult-onset, short-term dietary restriction reduces cell senescence in mice. | Q42017882 | ||
| Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin | Q42043023 | ||
| Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. | Q42091923 | ||
| Targeting the degradation of cyclin D1 will help to eliminate oncogene addiction | Q42158568 | ||
| TP53 and MTOR crosstalk to regulate cellular senescence | Q42356990 | ||
| Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. | Q42471935 | ||
| Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation | Q42489884 | ||
| Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies | Q42671862 | ||
| Targeting TOR dependence in cancer | Q42713384 | ||
| P3Kα: a driver of tumor metastasis? | Q42751622 | ||
| Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration | Q42805718 | ||
| Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine | Q42862829 | ||
| Chemoprevention meets glucose control | Q42920178 | ||
| Cancer: Long-term use of metformin could protect against breast cancer | Q43003591 | ||
| Rapamycin: killing two birds with one stone | Q43043684 | ||
| Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats | Q43148850 | ||
| Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. | Q43217487 | ||
| Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. | Q43218096 | ||
| The role of mTORC1 pathway in intestinal tumorigenesis. | Q43255342 | ||
| Shifting paradigms: the seeds of oncogene addiction | Q43265334 | ||
| MYC, microRNAs and glutamine addiction in cancers | Q43266702 | ||
| Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis | Q44086943 | ||
| Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. | Q44096696 | ||
| Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells | Q44141123 | ||
| Beta-adrenergic agonists regulate Na-K-ATPase via p70S6k. | Q44409328 | ||
| Beta blockers and breast cancer mortality: a population- based study | Q44536984 | ||
| Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways | Q21091205 | ||
| Genetic progression and the waiting time to cancer | Q21563505 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| A beta version of life: p110β takes center stage | Q24293200 | ||
| Extension of chronological life span in yeast by decreased TOR pathway signaling | Q24539948 | ||
| EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 | ||
| Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice | Q24597354 | ||
| Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy | Q24606104 | ||
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
| Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway | Q24643816 | ||
| Rapamycin fed late in life extends lifespan in genetically heterogeneous mice | Q24647805 | ||
| MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8 | Q24652474 | ||
| A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 | Q24657532 | ||
| Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study | Q24684767 | ||
| The genomic landscapes of human breast and colorectal cancers | Q27861078 | ||
| Genetic instabilities in human cancers | Q28131826 | ||
| Salicylate-induced growth arrest is associated with inhibition of p70s6k and down-regulation of c-myc, cyclin D1, cyclin A, and proliferating cell nuclear antigen | Q28174689 | ||
| Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies | Q28210611 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span | Q28272121 | ||
| Cancer genes and the pathways they control | Q28275089 | ||
| Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients | Q28282424 | ||
| The genetic landscape of the childhood cancer medulloblastoma | Q28301196 | ||
| Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 | ||
| Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis | Q36384467 | ||
| Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase | Q36623662 | ||
| mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer | Q36798847 | ||
| Late relapse of testis cancer | Q36813439 | ||
| Research by retrieving experiments | Q36831568 | ||
| Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer | Q36926010 | ||
| Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 | ||
| mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization | Q36995422 | ||
| Oncogene addiction: setting the stage for molecularly targeted cancer therapy | Q37031755 | ||
| Obesity, metabolic syndrome, and prostate cancer | Q37081269 | ||
| Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study | Q37101384 | ||
| Oncogene addiction | Q37152445 | ||
| Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? | Q37152449 | ||
| Insulin sensitivity as a key mediator of growth hormone actions on longevity | Q37153969 | ||
| "Targeting the absence" and therapeutic engineering for cancer therapy | Q37167162 | ||
| A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes | Q37169157 | ||
| Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells | Q37253119 | ||
| Prevention of cancer by inhibiting aging | Q37260020 | ||
| Reducing the weight of cancer: mechanistic targets for breaking the obesity-carcinogenesis link | Q37312792 | ||
| New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes | Q37319178 | ||
| Translation of the Philadelphia chromosome into therapy for CML. | Q37344094 | ||
| mTORC1 signaling governs hematopoietic stem cell quiescence | Q37344758 | ||
| Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. | Q37345878 | ||
| Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations | Q37390701 | ||
| Obesity and cancer: the role of dysfunctional adipose tissue | Q37597820 | ||
| Exploiting synthetic lethal interactions for targeted cancer therapy | Q37597842 | ||
| Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena | Q37715626 | ||
| Rapamycin and quasi-programmed aging: four years later | Q37740901 | ||
| Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality | Q37761003 | ||
| Radioprotection: smart games with death | Q37767574 | ||
| Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction | Q37770377 | ||
| Modern Approach to Metabolic Rehabilitation of Cancer Patients: Biguanides (Phenformin and Metformin) and Beyond | Q37783621 | ||
| Synthetic lethal approaches to breast cancer therapy | Q37801265 | ||
| Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal | Q37819818 | ||
| An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models | Q34769152 | ||
| Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress | Q35008361 | ||
| Tumor senescence as a determinant of drug response in vivo | Q35008920 | ||
| Paradoxical role of apoptosis in tumor progression | Q35014280 | ||
| Taking the study of cancer cell survival to a new dimension | Q35036517 | ||
| Reversing the aging stromal phenotype prevents carcinoma initiation | Q35052087 | ||
| Cyclotherapy: protection of normal cells and unshielding of cancer cells | Q35053628 | ||
| Cell senescence and hypermitogenic arrest | Q35097387 | ||
| Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer | Q35114450 | ||
| Visceral adiposity, insulin resistance and cancer risk | Q35133640 | ||
| Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis | Q35177312 | ||
| Aging-associated changes in hematopoiesis and leukemogenesis: what's the connection? | Q35188247 | ||
| Targeting cancer cells by exploiting their resistance | Q35192546 | ||
| Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis | Q35333423 | ||
| Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction | Q35409292 | ||
| Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. | Q35529084 | ||
| A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark | Q35623324 | ||
| Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial | Q35627411 | ||
| Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop | Q35640074 | ||
| Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival | Q35640094 | ||
| Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs | Q35640098 | ||
| Beta-adrenergic signaling, a novel target for cancer therapy? | Q35640106 | ||
| Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment | Q35640172 | ||
| Antiangiogenic therapy and tumor progression | Q35641618 | ||
| Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture | Q35679387 | ||
| Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers | Q35805316 | ||
| Pathways of apoptotic and non-apoptotic death in tumour cells | Q35852309 | ||
| Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? | Q35908976 | ||
| Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation | Q35924401 | ||
| Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation | Q35928960 | ||
| Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance | Q35945000 | ||
| How cancer could be cured by 2015. | Q36012188 | ||
| Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. | Q36070998 | ||
| Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance | Q36315504 | ||
| Cell cycle arrest is not senescence | Q37836231 | ||
| A longer and healthier life with TOR down-regulation: genetics and drugs | Q37856372 | ||
| Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis | Q37939075 | ||
| mTOR signaling in disease | Q37941273 | ||
| Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans | Q38358191 | ||
| Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression | Q39430569 | ||
| Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells | Q39488905 | ||
| Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib | Q39569161 | ||
| Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. | Q39593069 | ||
| Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs | Q39604676 | ||
| mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. | Q39616865 | ||
| Weak p53 permits senescence during cell cycle arrest | Q39635569 | ||
| p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate | Q39646025 | ||
| Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner | Q39707409 | ||
| Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. | Q39732167 | ||
| Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential | Q39739137 | ||
| Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. | Q39816293 | ||
| Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence | Q39845659 | ||
| Rapamycin decelerates cellular senescence | Q39846812 | ||
| The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells | Q39902046 | ||
| Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis | Q39908034 | ||
| Growth stimulation leads to cellular senescence when the cell cycle is blocked | Q39925937 | ||
| Metformin, insulin, breast cancer and more... | Q39986644 | ||
| Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells | Q40050621 | ||
| Non-oncogene addiction and the stress phenotype of cancer cells | Q40077390 | ||
| Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation | Q40252256 | ||
| Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. | Q40480010 | ||
| Apoptosis as a goal of cancer therapy | Q40574012 | ||
| Apoptosis in cancer therapy: crossing the threshold | Q40694262 | ||
| Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor | Q40711655 | ||
| Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells | Q40787082 | ||
| A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy | Q40929887 | ||
| Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L) | Q28369231 | ||
| Pseudo-DNA damage response in senescent cells | Q28583844 | ||
| DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence | Q28972513 | ||
| Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity | Q29614241 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies | Q29614869 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor | Q29615559 | ||
| Tumor metastasis: molecular insights and evolving paradigms | Q29615908 | ||
| Ribosomal protein S6 kinase 1 signaling regulates mammalian life span | Q29615975 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| Genetics: influence of TOR kinase on lifespan in C. elegans | Q29616619 | ||
| Principles of cancer therapy: oncogene and non-oncogene addiction | Q29616779 | ||
| Cancer metastasis: building a framework | Q29616783 | ||
| The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
| Restoration of p53 function leads to tumour regression in vivo | Q29618727 | ||
| Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? | Q30884073 | ||
| p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin | Q31008408 | ||
| Validation of anti-aging drugs by treating age-related diseases | Q33588700 | ||
| mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells | Q33609242 | ||
| Fasting and cancer treatment in humans: A case series report. | Q33627959 | ||
| Extension of chronological life span by reduced TOR signaling requires down-regulation of Sch9p and involves increased mitochondrial OXPHOS complex density | Q33627993 | ||
| Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster | Q33665807 | ||
| DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion | Q33759285 | ||
| Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials | Q33767211 | ||
| Apoptosis and drug response | Q33767800 | ||
| Dysregulation of apoptosis in cancer | Q33773397 | ||
| Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer | Q33788519 | ||
| Apoptosis and cancer drug targeting | Q33801122 | ||
| Genetic instability and darwinian selection in tumours | Q33804007 | ||
| Rapamycin extends maximal lifespan in cancer-prone mice | Q33816255 | ||
| Apoptosis in cancer | Q33846227 | ||
| Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes | Q33849666 | ||
| With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging | Q33912952 | ||
| Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs | Q33939126 | ||
| Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging | Q33946993 | ||
| Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells | Q33952270 | ||
| Cell death beyond apoptosis | Q34002890 | ||
| Paradoxical suppression of cellular senescence by p53 | Q34006762 | ||
| Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. | Q34017915 | ||
| The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. | Q34024558 | ||
| Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications | Q34072984 | ||
| Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). | Q34097445 | ||
| Conceptual biology: unearthing the gems | Q34120924 | ||
| Oncogenic resistance to growth-limiting conditions | Q34126792 | ||
| mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. | Q34129574 | ||
| Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. | Q34182185 | ||
| Metformin and other biguanides in oncology: advancing the research agenda | Q34196114 | ||
| Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells | Q34196369 | ||
| Exploiting cancer cell cycling for selective protection of normal cells. | Q34271284 | ||
| Accumulation of driver and passenger mutations during tumor progression | Q34276850 | ||
| Differences underlying EGFR and HER2 oncogene addiction | Q34307542 | ||
| Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors | Q34369172 | ||
| Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? | Q34400252 | ||
| Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis. | Q34411132 | ||
| PI3Kα inhibitors that inhibit metastasis | Q34416746 | ||
| Metformin for aging and cancer prevention | Q34424886 | ||
| A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. | Q34424910 | ||
| p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors | Q34432427 | ||
| Apoptosis: a link between cancer genetics and chemotherapy | Q34520432 | ||
| Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice | Q34554315 | ||
| Sirolimus for Kaposi's sarcoma in renal-transplant recipients | Q34556363 | ||
| Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice | Q34560435 | ||
| If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells | Q34625589 | ||
| Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 | ||
| Role of TOR signaling in aging and related biological processes in Drosophila melanogaster | Q34677806 | ||
| Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? | Q34683956 | ||
| p53 determines multidrug sensitivity of childhood neuroblastoma | Q34708242 | ||
| Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras | Q34763792 | ||
| Antagonistic drug combinations that select against drug resistance: from bacteria to cancer | Q80657038 | ||
| Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors | Q81489492 | ||
| Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice | Q84271209 | ||
| Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver | Q84432396 | ||
| Targeted therapies: Using β-blockers to inhibit breast cancer progression | Q84639335 | ||
| Phosphatidylinositol 3-kinase in angiotensin II-induced hypertrophy of vascular smooth muscle cells | Q44614710 | ||
| Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus | Q44696133 | ||
| Do cells need CDK2 and ... Bcr-Abl? | Q44699399 | ||
| Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
| Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. | Q46008332 | ||
| Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. | Q46015488 | ||
| Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. | Q46124744 | ||
| Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues | Q46166166 | ||
| Metformin slows down aging and extends life span of female SHR mice. | Q46410425 | ||
| Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin | Q46450365 | ||
| Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer | Q46472074 | ||
| Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel | Q46495694 | ||
| Colorectal cancer: mutations in a signalling pathway | Q46644995 | ||
| Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. | Q46670120 | ||
| Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice | Q46752587 | ||
| TORgeting oncogene addiction for cancer therapy | Q46940620 | ||
| Complexity of the TOR signaling network | Q46975015 | ||
| Oncogenic K-ras "addiction" and synthetic lethality | Q47155289 | ||
| Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. | Q47294305 | ||
| Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. | Q48925268 | ||
| Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. | Q51385394 | ||
| RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. | Q51761211 | ||
| Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. | Q52276783 | ||
| Oncogenic shock: turning an activated kinase against the tumor cell. | Q52290542 | ||
| Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. | Q53085711 | ||
| Rapamycin-induced glucose intolerance: hunger or starvation diabetes. | Q53199806 | ||
| Inhibition of ras-induced proliferation and cellular transformation by p16INK4. | Q53466632 | ||
| Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. | Q54068368 | ||
| Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. | Q54090855 | ||
| Mechanisms of apoptosis avoidance in cancer. | Q54107829 | ||
| Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. | Q54361550 | ||
| Dynamics of genetic instability in sporadic and familial colorectal cancer. | Q54528454 | ||
| From growing to secreting: new roles for mTOR in aging cells. | Q54577655 | ||
| p53 is a suppressor of inflammatory response in mice. | Q54672229 | ||
| Perspectives on cellular senescence and short term dietary restriction in adults. | Q55496565 | ||
| Activation of mammalian target of rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes. | Q64957460 | ||
| Angiotensin and cell growth: a link to cardiovascular hypertrophy? | Q67914040 | ||
| Activation of p70 S6 protein kinase is necessary for angiotensin II-induced hypertrophy in neonatal rat cardiac myocytes | Q71006805 | ||
| Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice | Q71239353 | ||
| Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells | Q71680834 | ||
| Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy | Q71807337 | ||
| Intracellular signaling of angiotensin II-induced p70 S6 kinase phosphorylation at Ser(411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular signal-regulated kinase, and Akt | Q73279797 | ||
| beta-agonists regulate Na,K-ATPase via novel MAPK/ERK and rapamycin-sensitive pathways | Q73303529 | ||
| Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells | Q74052282 | ||
| Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3 | Q74213469 | ||
| Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs | Q74737230 | ||
| Activation of p70(S6) kinase by beta-adrenoceptor agonists on adult cardiomyocytes | Q77502409 | ||
| Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer | Q79339657 | ||
| The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man | Q79848490 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1352-1367 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | NCI's provocative questions on cancer: some answers to ignite discussion | |
| P478 | volume | 2 |
| Q43086657 | Abdominal radiation and diabetes: one more piece in the puzzle |
| Q36736351 | Answering the ultimate question "what is the proximal cause of aging?" |
| Q34227603 | Anti-apoptotic effects of PCP4/PEP19 in human breast cancer cell lines: a novel oncotarget |
| Q28385362 | Arsenic-induced sub-lethal stress reprograms human bronchial epithelial cells to CD61¯ cancer stem cells |
| Q36926148 | Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions |
| Q26823867 | Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment |
| Q36356167 | Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression |
| Q36189324 | Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents |
| Q37577609 | Distribution of Iron Oxide Core-Titanium Dioxide Shell Nanoparticles in VX2 Tumor Bearing Rabbits Introduced by Two Different Delivery Modalities. |
| Q36392155 | Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment |
| Q38663615 | Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. |
| Q36210986 | High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. |
| Q34956692 | High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients |
| Q35805426 | Improvement in vision: a new goal for treatment of hereditary retinal degenerations |
| Q36557513 | Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death |
| Q42236265 | Just like the rest of evolution in Mother Nature, the evolution of cancers may be driven by natural selection, and not by haphazard mutations |
| Q26766238 | Learning about the Importance of Mutation Prevention from Curable Cancers and Benign Tumors |
| Q28480735 | Metformin in obesity, cancer and aging: addressing controversies |
| Q35793665 | Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction |
| Q33688566 | Minoxidil may suppress androgen receptor-related functions |
| Q34619344 | Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia |
| Q34786445 | Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. |
| Q26801291 | Protecting the normal in order to better kill the cancer |
| Q36187549 | Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN) |
| Q26866151 | Rapalogs in cancer prevention: anti-aging or anticancer? |
| Q34392470 | Selective anti-cancer agents as anti-aging drugs |
| Q34483751 | Selective methioninase-induced trap of cancer cells in S/G2 phase visualized by FUCCI imaging confers chemosensitivity |
| Q33952918 | Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness |
| Q37073302 | Suppression of Kaposi's Sarcoma-Associated Herpesvirus Infection and Replication by 5'-AMP-Activated Protein Kinase |
| Q33755220 | TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities |
| Q34391710 | TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists |
| Q33977001 | Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma |
| Q28553655 | The Synthetic β-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways |
| Q34956816 | Therapeutic potential of ERK5 targeting in triple negative breast cancer |
| Q35741664 | Traditional Chinese medicine herbal mixture LQ arrests FUCCI-expressing HeLa cells in G₀/G₁ phase in 2D plastic, 2.5D Matrigel, and 3D Gelfoam culture visualized with FUCCI imaging |
| Q36209128 | Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? |
| Q37118741 | Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging |
| Q36189385 | Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy |
| Q36234051 | Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells |
| Q28395443 | Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents |
Search more.